CombiMatrix to provide tests for American Pathology Partners


CombiMatrix (CBMX) will provide its tests for analyzing miscarriages to American Pathology Partners (AP2), which is creating a nationwide network of anatomic pathology laboratories.

The partnership for the chromosomal microarray analysis (CMA) tests is effective immediately and is starting with UniPath, AP2's flagship laboratory in Denver.

CombiMatrix's shares are +5.25%. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs